What GATT Technologies does

GATT Technologies is a Dutch medical device company founded in 2011 and headquartered in Nijmegen, Netherlands, employing between 11 and 50 people. The company develops surgical technologies addressing tissue management, hemostasis, and wound closure, with its flagship product line built around SURGICEL Powder — an oxidized regenerated cellulose absorbable hemostat used adjunctively in surgical procedures to control capillary, venous, and small arterial hemorrhage when conventional methods of control are impractical or ineffective. GATT's portfolio extends across wound closure solutions, biosurgery products, surgical stapling, surgical energy devices, antimicrobial dressings (including the Biopatch protective disk with chlorhexidine gluconate), and surgical instruments, addressing at least ten surgical specialty verticals including bariatric, cardiovascular, colon and rectal, gynecology, head and neck, interventional pulmonology, orthopaedics, plastic, thoracic, and veterinary surgery.

The company's most distinctive technology component is the SURGICEL Endoscopic Applicator, a specialized delivery device that enables SURGICEL Powder to be applied through a 5mm or larger trocar during laparoscopic and other endoscopic procedures, extending the hemostat's utility into minimally invasive surgery. The products are sold through enterprise B2B channels targeting hospitals, surgical centers, and healthcare systems globally. In May 2020, GATT raised approximately $11.46 million in a funding round led by NGI with participation from Johnson & Johnson Innovation and OostNL, and the company appears to have been subsequently integrated into Johnson & Johnson MedTech's Surgery division, as the J&J MedTech Surgery portal now redirects from the /companies/gatt-tech URL and lists GATT's SURGICEL products as part of the J&J surgery portfolio. Johan Bender is identified as founder and CTO.

Pricing is not publicly disclosed, consistent with enterprise medical device sales conducted through direct sales relationships and distributor channels rather than list-price transactions. The business model rests on regulated medical device commercialization backed by clinical evidence, surgeon training programs, and established hospital formulary adoption — a classic medtech go-to-market motion amplified by J&J's global sales force and medical device distribution network.

Name

GATT Technologies

Website

https://gatt-tech.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

GATT Technologies is a Dutch medical device company developing surgical hemostats, wound closure products, and endoscopic delivery devices, including the SURGICEL Powder absorbable hemostat line, serving hospitals and surgical centers across multiple specialties, and now integrated into Johnson & Johnson MedTech.

Ownership category

akta.pro rank

Product category

Surgical Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Medical devices
• Surgical hemostats
• Biosurgery products
• Wound closure devices
• Surgical instruments

Headquarters

HQ city

Nijmegen

HQ country

Netherlands

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations

Distribution channels2 records

Marketing channels5 records

Core offering

GATT Technologies is a privately held medical device company founded in 2011 in Nijmegen, Netherlands, operating with 11–50 employees. It develops medical devices and technologies in surgical specialties. The company's original web presence has been redirected under the Johnson & Johnson MedTech (J&J MedTech) surgery division, indicating integration into J&J's surgical portfolio covering wound closure, biosurgery (absorbable hemostats), surgical stapling, surgical energy, and surgical instruments.

Product overview

J&J MedTech's surgery division offers a comprehensive portfolio of surgical products organized across multiple categories including Wound Closure, Biosurgery, Surgical Stapling, Surgical Energy, Antimicrobial Dressing, and Surgical Instruments. The portfolio is anchored by SURGICEL Powder Absorbable Hemostat, an oxidized regenerated cellulose product used adjunctively for hemorrhage control, and the SURGICEL Endoscopic Applicator for laparoscopic delivery. These products serve multiple surgical specialties including bariatric, cardiovascular, colon & rectal, gynecology, head & neck, interventional pulmonology, orthopaedics, plastic, thoracic, and veterinary procedures. The company has over 135 years of experience driving innovations in surgical care.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical device development services (under GATT Technologies brand)

Segments10 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Direct peers

• Baxter International: Baxter markets FLOSEAL and TISSEEL, two of the dominant surgical hemostats and sealants globally. Direct competitor to GATT's polymer hemostat technology in the same surgical use cases.
• Johnson & Johnson (Ethicon): J&J's Ethicon division sells the SURGICEL oxidized regenerated cellulose hemostat franchise — the incumbent product GATT's polymer platform is most directly positioned against. Also a strategic investor in GATT.
• Integra LifeSciences: Integra sells dural sealants, hemostatic agents, and surgical regenerative products, directly competing with GATT in the surgical hemostasis and tissue management space.
• Artivion (formerly CryoLife): Artivion markets BioGlue surgical adhesive and hemostatic products, directly comparable to GATT's polymer-based sealant/hemostat platform in surgical use cases.

Broad incumbents

• Medtronic: Through the legacy Covidien portfolio, Medtronic offers surgical hemostats and sealants and competes across multiple surgical specialties where GATT's products are positioned.
• Becton Dickinson (BD): BD's surgery and biosurgery portfolio includes hemostatic products and surgical sealants. As a diversified medtech incumbent, BD competes with GATT across multiple surgical use cases.
• Stryker: Stryker's surgical portfolio (expanded via Cohera Medical acquisition) competes in sealants and hemostats, and its scale makes it both a competitor and a potential strategic acquirer of GATT.

Emerging players

• Arch Therapeutics: Arch Therapeutics develops self-assembling peptide hemostatic agents (AC5), a similar small-cap, single-platform competitor in absorbable surgical hemostats — the closest size and stage comparable to GATT.
• Cohera Medical: Cohera developed synthetic surgical sealants and tissue adhesives before its acquisition by Stryker — a relevant strategic-exit comparable for a niche polymer sealant company like GATT.
• TissueSeal: TissueSeal focuses on surgical sealants and hemostats using synthetic polymer platforms, providing a smaller-scale technology-comparable peer in the same hemostat/sealant category as GATT.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/gatt-technologies-bv

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GATT Technologies